The Japan Statin Treatment Against Recurrent Stroke (J-STARS): A Multicenter, Randomized, Open-label, Parallel-group Study

EBioMedicine

Volumn 2, Issue 9, 2015, Pages 1071-1078

  Hosomi, Naohisa ^a   Nagai, Yoji ^b   Kohriyama, Tatsuo ^c   Ohtsuki, Toshiho ^d   Aoki, Shiro ^a   Nezu, Tomohisa ^a   Maruyama, Hirofumi ^a   Sunami, Norio ^e   Yokota, Chiaki ^f   Kitagawa, Kazuo ^g   Terayama, Yasuo ^h   Takagi, Makoto ⁱ   Ibayashi, Setsuro ^j   Nakamura, Masakazu ^f   Origasa, Hideki ^k   Fukushima, Masanori ^b   Mori, Etsuro ^l   Minematsu, Kazuo ^f   Uchiyama, Shinichiro ^m   Shinohara, Yukito ⁿ   Yamaguchi, Takenori ^f   Matsumoto, Masayasu ^a   more..

^a HIROSHIMA UNIVERSITY   (Japan)

^b Translational Research Informatics Center Foundation for Biomedical Research and Innovation   (Japan)

^c Hiroshima City Rehabilitation Hospital   (Japan)

^d KINKI UNIVERSITY   (Japan)

^e Matsuyama Shimin Hospital   (Japan)

^f NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^g TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^h IWATE MEDICAL UNIVERSITY   (Japan)

ⁱ SAISEIKAI CENTRAL HOSPITAL   (Japan)

^j Seiai Rehabilitation Hospital   (Japan)

^k UNIVERSITY OF TOYAMA   (Japan)

^l TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^m INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

ⁿ Federation of National Public Service Personnel Mutual Aid Associations   (Japan)

more..

Author keywords

Atherothrombotic infarction; Cholesterol; Hemorrhagic stroke; Ischemic stroke; Statin

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; TRIACYLGLYCEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL INJURY; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DIET THERAPY; DISEASE SEVERITY; EXERCISE; FEMALE; FOLLOW UP; FUNDING; HEART INFARCTION; HUMAN; LACUNAR STROKE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SCORING SYSTEM; TRANSIENT ISCHEMIC ATTACK; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; COMPLICATION; ETHNOLOGY; JAPAN; KAPLAN MEIER METHOD; MIDDLE AGED; OUTCOME ASSESSMENT; PROCEDURES; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA; STROKE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN ISCHEMIA; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PRAVASTATIN; PROPORTIONAL HAZARDS MODELS; RECURRENCE; STROKE;

EID: 84953739411     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.08.006     Document Type: Article

References (34)

1. Albert M.A., Danielson E., Rifai N., et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001, 286:64-70.
2. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group The Antihypertensive Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002, 288:2998-3007.
3. Amarenco P., Labreuche J., Lavallee P., et al. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004, 35:2902-2909.
4. Amarenco P., Bogousslavsky J., Callahan A., et al. High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. 2006, 355:549-559.
5. Amarenco P., Benavente O., Goldstein L.B., et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke 2009, 40:1405-1409.
6. Boekholdt S.M., Hovingh G.K., Mora S., et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J. Am. Coll. Cardiol. 2014, 64:485-494.
7. Byington R.P., Furberg C.D., Crouse J.R., et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am. J. Cardiol. 1995, 76:54C-59C.
8. Collins R., Armitage J., Parish S., et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004, 363:757-767.
9. Corvol J.C., Bouzamondo A., Sirol M., et al. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch. Intern. Med. 2003, 163:669-676.
10. Crisby M., Nordin-Fredriksson G., Shah P.K., et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001, 103:926-933.
11. Crouse J.R., Raichlen J.S., Riley W.A., et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007, 297:1344-1353.
12. European Stroke Organisation Executive Committee, ESO Writing Committee Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc. Dis. 2008, 25:457-507.
13. Forette F., Seux M.L., Staessen J.A., et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998, 352:1347-1351.
14. Ikeda Y., Shimada K., Teramoto T., et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 2014, 312:2510-2520.
15. Kernan W.N., Ovbiagele B., Black H.R., et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014, 45:2160-2236.
16. Kushiro T., Mizuno K., Nakaya N., et al. Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Hypertension 2009, 53:135-141.
17. Kuwashiro T., Sugimori H., Ago T., et al. Risk factors predisposing to stroke recurrence within one year of non-cardioembolic stroke onset: the Fukuoka Stroke Registry. Cerebrovasc. Dis. 2012, 33:141-149.
18. Manktelow B.N., Potter J.F. Interventions in the management of serum lipids for preventing stroke recurrence. Cochrane Database Syst. Rev. 2009, CD002091.
19. McGuinness B., Craig D., Bullock R., et al. Statins for the treatment of dementia. Cochrane Database Syst. Rev. 2014, 7:CD007514.
20. Nagai Y., Kohriyama T., Origasa H., et al. Rationale, design, and baseline features of a randomized controlled trial to assess the effects of statin for the secondary prevention of stroke: the Japan Statin Treatment Against Recurrent Stroke (J-STARS). Int. J. Stroke 2014, 9:232-239.
21. Nakamura H., Arakawa K., Itakura H., et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006, 368:1155-1163.
22. Nishimura R., Sone H., Nakagami T., et al. Importance of high-density lipoprotein cholesterol control during pravastatin treatment in hypercholesterolemic Japanese with type 2 diabetes mellitus: a post hoc analysis of MEGA study. Diabetes Res. Clin. Pract. 2013, 100:e31-e33.
23. Nomura E., Suzuki A., Inoue I., et al. Subsequent vascular events after ischemic stroke: the Japan Statin Treatment Against Recurrent Stroke-Longitudinal. J. Stroke Cerebrovasc. Dis. 2015, 24:473-479.
24. Pearson T.A. Primary and secondary prevention of coronary artery disease: trials of lipid lowering with statins. Am. J. Cardiol. 1998, 82:28S-30S.
25. Plehn J.F., Davis B.R., Sacks F.M., et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation 1999, 99:216-223.
26. Ridker P.M., Rifai N., Pfeffer M.A., et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999, 100:230-235.
27. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
28. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623-1630.
29. Shinohara Y., Katayama Y., Uchiyama S., et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010, 9:959-968.
30. Tsuda Y., Satoh K., Kitadai M., et al. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis 1996, 122:225-233.
31. Tzourio C., Anderson C., Chapman N., et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch. Intern. Med. 2003, 163:1069-1075.
32. Uchiyama S., Nakaya N., Mizuno K., et al. Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial. J. Neurol. Sci. 2009, 284:72-76.
33. Usherwood T. National guidelines for the management of absolute cardiovascular disease risk. Med. J. Aust. 2013, 199:243-244.
34. White H.D., Simes R.J., Anderson N.E., et al. Pravastatin therapy and the risk of stroke. N. Engl. J. Med. 2000, 343:317-326.